Janus Henderson Group PLC Rapt Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$6.87 - $26.45 $6 - $26	1 Added 0.01%	16,003 $143,000
Q4 2023 Feb 14, 2024	SELL	$11.28 - $25.46 $146 - $330	-13 Reduced 0.08%	16,002 $397,000
Q3 2023 Nov 14, 2023	BUY	$16.34 - $24.66 $81 - $123	5 Added 0.03%	16,015 $266,000
Q2 2023 Aug 14, 2023	SELL	$16.06 - $21.61 $529 - $713	-33 Reduced 0.21%	16,010 $299,000
Q1 2023 May 15, 2023	BUY	$17.19 - $30.8 $275,779 - $494,124	16,043 New	16,043 $294,000

105

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $35.6M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.